- Home
- BLND vs PBYI Comparison
BLND vs PBYI Comparison
Compare BLND & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BLND | PBYI |
|---|---|---|
| Founded | 2012 | 2010 |
| Country | United States | United States |
| Employees | N/A | 179 |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 411.6M | 413.3M |
| IPO Year | 2021 | 2011 |
Fundamental Metrics
Financial Performance| Metric | BLND | PBYI |
|---|---|---|
| Price | $1.66 | $8.73 |
| Analyst Decision | Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $4.13 | N/A |
| AVG Volume (30 Days) | ★ 2.2M | 304.4K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 58.33 | N/A |
| EPS | N/A | ★ 0.08 |
| Revenue | ★ $123,585,000.00 | $27,685,000.00 |
| Revenue This Year | $12.62 | N/A |
| Revenue Next Year | $14.00 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.18 | $3.71 |
| 52 Week High | $4.49 | $8.75 |
Technical Indicators
Market Signals| Indicator | BLND | PBYI |
|---|---|---|
| Relative Strength Index (RSI) | 59.57 | 54.32 |
| Support Level | $1.60 | $7.64 |
| Resistance Level | $2.05 | $8.53 |
| Average True Range (ATR) | 0.10 | 0.36 |
| MACD | 0.02 | -0.04 |
| Stochastic Oscillator | 68.29 | 52.99 |
Price Performance
Historical ComparisonAbout BLND Blend Labs Inc.
Blend Labs Inc is a cloud-based platform software platform that powers the digital interface between financial services firms and consumers. It supports and simplifies applications for mortgages, consumer loans, and deposit accounts. Its operating segment is Blend Platform segment which comprises a suite of products that power the entire origination process from back-end workflows to consumer experience. The key revenue for the company is generated from the Blend Platform segment. Company has it's assets in united states, India and Mexico regions.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also, it is developing Alisertib, a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis, resulting in apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.